In vitro anti-inflammatory and anticancer activities of extracts of Acalypha alopecuroidea (Euphorbiaceae)

International Journal of Oncology

Volumn 35, Issue 4, 2009, Pages 881-891

  Madlener, Sibylle ^a   Svacinová, Jana ^c   Kitner, Miloslav ^c   Kopecky, Jirí ^d,e   Eytner, Ruth ^a   Lackner, Andreas ^b   Vo, Than Phuong Nha ^a   Frisch, Richard ^f   Grusch, Michael ^b   De Martin, Rainer ^a   Dolezal, Karel ^c   Strnad, Miroslav ^c   Krupitza, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d Laboratory of Algal Biotechnology   (India)

^e UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^f Institute for Ethnobiology   (Guatemala)

Author keywords

Acalypha alopecuroidea; Anti inflammatory activity; Anticancer activity; Cancer; CEM cells; MCF 7 cells

Indexed keywords

ACALYPHA ALOPECUROIDEA EXTRACT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CASPASE 3; CELL CYCLE PROTEIN; CHECKPOINT KINASE 2; CYCLIN A; CYCLIN D1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; METHANOL; PLANT EXTRACT; PROTEIN CDC25A; TETRAHYDROFURAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACALYPHA ALOPECUROIDEA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CENTRAL AMERICA; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; EUPHORBIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLORESCENCE; PLANT LEAF; PLANT ROOT; PLANT STEM; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; VALIDATION STUDY;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CDC25 PHOSPHATASES; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYCLIN A; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; E-SELECTIN; ENDOTHELIAL CELLS; EUPHORBIACEAE; FEMALE; HL-60 CELLS; HUMANS; INFLORESCENCE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MUTATION; PLANT LEAVES; PLANT SHOOTS; PROTEIN-SERINE-THREONINE KINASES; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70449339407     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000403     Document Type: Article

References (46)

1. Gilani AH and Rahman AU: Trends in ethnopharmocology. J Ethnopharmacol 100: 43-49, 2005.
2. Kim EC, Min JK, Kim TY, Lee SJ, Yang HO, Han S, Kim YM and Kwon YG: [6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 335: 300-308, 2005. (Pubitemid 41140221)
3. Chapple IL: Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol 24: 287-296, 1997. (Pubitemid 127731526)
4. Benzi G and Moretti A: Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 16: 661-674, 1995.
5. Park SW, Kim SH, Park KH, Kim SD, Kim JY, Baek SY, Chung BS and Kang CD: Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci Lett 363: 243-246, 2004. (Pubitemid 38746521)
6. Madlener S, Illmer C, Horvath Z, Saiko P, Losert A, Herbacek I, Grusch M, Elford HL, Krupitza G, Bernhaus A, Fritzer- Szekeres M and Szekeres T: Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. Cancer Lett 245: 156-162, 2007. (Pubitemid 44959349)
7. Adesina SK, Idowu O, Ogundaini AO, Oladimeji H, Olugbade TA, Onawunmi GO and Pais M: Antimicrobial constituents of the leaves of Acalypha wilkesiana and Acalypha hispida. Phytother Res 14: 371-374, 2000.
8. Gutierrez-Lugo MT, Singh MP, Maiese WM and Timmermann BN: New antimicrobial cycloartane triterpenes from Acalypha communis. J Nat Prod 65: 872-875, 2002.
9. Mosquera OM, Correa YM, Buitrago DC and Niño J: Antioxidant activity of twenty five plants from Colombian biodiversity. Mem Inst Oswaldo Cruz 102: 631-634, 2007.
10. Mothana AR, Salah A, Abdo A, Hasson S, Faisal M, Althawab N, Sama A, Alaghbari Z and Lindequist U: Antimicrobial, antioxidant and cytotoxic activities and phytochemical screening of some Yemeni medicinal plants. eCAM Advance Access, 1-8, 2008.
11. Wiart C, Hannah A, Yassim M, Hamimah H and Sulaiman M: Antimicrobial activity of Acalypha siamensis Oliv. ex Gage. J Ethnopharmacol 95: 285-286, 2004.
12. Akinyemi KO, Oladapo O, Okwara CE, Ibe CC and Fasure KA: Screening of crude extracts of six medicinal plants used in South-West Nigerian unorthodox medicine for anti-methicillin resistant Staphylococcus aureus activity. BMC Complement Altern Med 11: 5-6, 2005 (Pubitemid 41364088)
13. Navarro MC, Montilla MP, Cabo MM, Galisteo M, Cáceres A, Morales C and Berger I: Antibacterial, antiprotozoal and antioxidant activity of five plants used in Izabal for infectious diseases. Phytother Res 17: 325-329, 2003. (Pubitemid 36565335)
14. Arvigo R and Balick M: Rainforest Remedies. Lotus Press, Twin Lakes, WI, 1998.
15. Chapuis JC, Sordat B and Hostettmann K: Screening for cytotoxic activity of plants used in traditional medicine. J Ethnopharmacol 23: 273-284, 1988. (Pubitemid 18222443)
16. Zhang JS, Nelson M, Wang L, Liu W, Qian CP, Shridhar V, Urrutia R and Smith DI: Identification and chromosomal localization of CTNNAL1, a novel protein homologous to alpha-catenin. Genomics 54: 149-154, 1998. (Pubitemid 28536205)
17. Maier S, Strasser S, Saiko P, Leisser C, Sasgary S, Grusch M, Madlener S, Bader Y, Hartmann J, Schott H, Mader RM, Szekeres T, Fritzer-Szekeres M and Krupitza G: Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC. Apoptosis 11: 427-440, 2006.
18. Brennan FM and McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545, 2008.
19. Ardizzone S and Bianchi Porro G: Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286, 2005. (Pubitemid 41571985)
20. Victor FC, Gottlieb AB and Menter A: Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 21: 392-397, 2003.
21. Bernert H, Sekikawa K, Radcliffe RA, Iraqi F, You M and Malkinson AM: Tnfa and Il-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog 38: 117-123, 2003. (Pubitemid 37409822)
22. Sturm JW, Magdeburg R, Berger K, Petruch B, Samel S, Bönninghoff R, Keese M, Hafner M and Post S: Influence of TNFA on the formation of liver metastases in a syngenic mouse model. Int J Cancer 107: 11-21, 2003. (Pubitemid 37100080)
23. Ghaderi M, Nikitina L, Peacock CS, Hjelmström P, Hallmans G, Wiklund F, Lenner P, Blackwell JM, Dillner J and Sanjeevi CB: Tumor necrosis factor α-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev 9: 1067-1070, 2000. (Pubitemid 30783537)
24. Szlosarek PW and Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4: 565-573, 2003. (Pubitemid 38351714)
25. Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F and Gore M: Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 25: 4542-4549, 2007. (Pubitemid 350035310)
26. Rajan S, Ye J, Bai S, Huang F and Guo YL: NF-kappaB, but not p38 MAP kinase, is required for TNF-alpha-induced expression of cell adhesion molecules in endothelial cells. J Cell Biochem 105: 477-486, 2008.
27. Nam NH: Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6: 945-951, 2006.
28. Rossi B and Constantin G: Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm Allergy Drug Targets 7: 85-93, 2008.
29. Austrup F, Vestweber D, Borges E, Löhning M, Bräuer R, Herz U, Renz H, Hallmann R, Scheffold A, Radbruch A and Hamann A: P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 385: 81-83, 1997. (Pubitemid 27024558)
30. Falck J, Mailand N, Syljuåsen RG, Bartek J and Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410: 842-847, 2001. (Pubitemid 32303786)
31. Busino L, Chiesa M, Draetta GF and Donzelli M: Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23: 2050-2056, 2004. (Pubitemid 38496734)
32. Karlsson-Rosenthal C and Millar JB: Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 16: 285-292, 2006. (Pubitemid 43868088)
33. Chen CR, Wang W, Rogoff HA, Li X, Mang W and Li CJ: Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: Checkpoint activation as a strategy against cancer. Cancer Res 65: 6017-6021, 2005. (Pubitemid 40994384)
34. Ray D and Kiyokawa H: CDC25A levels determine the balance of proliferation and checkpoint response. Cell Cycle 6: 3039-3042, 2007.
35. Hüttenbrenner S, Maier S, Leisser C, Polgar D, Strasser S, Grusch M and Krupitza G: The evolution of cell death programs as prerequisites of multicellularity. Rev Mutat Res 543: 235-249, 2003. (Pubitemid 36645082)
36. Frisch SM and Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 13: 555-562, 2001.
37. Valentijn AJ, Zouq N and Gilmore AP: Anoikis. Biochem Soc Trans 32: 421-425, 2004.
38. Grusch M, Polgar D, Gfatter S, Leuhuber K, Huettenbrenner S, Leisser C, Fuhrmann G, Kassie F, Steinkellner H, Smid K, Peters GJ, Jayaram H, Klepal T, Szekeres T, Knasmüller S and Krupitza G: Maintainance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ 9: 169-178, 2002. (Pubitemid 34144776)
39. Zambon A, Gervois P, Pauletto P, Fruchart JC and Staels B: Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26: 977-986, 2006. (Pubitemid 43732101)
40. Johnson GL and Nakamura K: The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 1773: 1341-1348, 2007. (Pubitemid 47125977)
41. Parker MA, Deane NG, Thompson EA, Whitehead RH, Mithani SK, Washington MK, Datta PK, Dixon DA and Beauchamp RD: Overexpression of cyclin D1 regulates Cdk4 protein synthesis. Cell Prolif 36: 347-360, 2003.
42. Nelsen CJ, Kuriyama R, Hirsch B, Negron VC, Lingle WL, Goggin MM, Stanley MW and Albrecht JH: Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 280: 768-776, 2005. (Pubitemid 40165045)
43. Moreno-Bueno G, Rodríguez-Perales S, Sánchez-Estévez C, Hardisson D, Sarrió D, Prat J, Cigudosa JC, Matias-Guiu X and Palacios J: Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22: 6115-6118, 2003. (Pubitemid 37175891)
44. Agner J, Falck J, Lukas J and Bartek J: Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp Cell Res 302: 162-169, 2005. (Pubitemid 39550459)
45. Kasibhatla S and Tseng B: Why target apoptosis in cancer treatment? Mol Cancer Ther 2: 573-580, 2003.
46. Pellegata NS, Antoniono RJ, Redpath JS and Stanbridge EJ: DNA damage and p53-mediated cell cycle arrest: Areevaluation. Proc Natl Acad Sci USA 93: 15209-15214, 1996.